99 related articles for article (PubMed ID: 21431280)
1. Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma.
Kim HS; Kim JO; Lee DH; Lee HC; Kim HJ; Kim JH; Jang YS; Lee JM; Kim SY; Kim YS
Oncol Rep; 2011 Jun; 25(6):1639-44. PubMed ID: 21431280
[TBL] [Abstract][Full Text] [Related]
2. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
[TBL] [Abstract][Full Text] [Related]
3. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
Kim KH; Suh KS; Kang DW; Kang DY
Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
[TBL] [Abstract][Full Text] [Related]
5. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
6. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
8. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma.
Chang H; Lee H; Yoon SO; Kim H; Kim A; Kim BH
Hum Pathol; 2012 Jan; 43(1):89-95. PubMed ID: 21774961
[TBL] [Abstract][Full Text] [Related]
9. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
10. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
11. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.
Cradic KW; Milosevic D; Rosenberg AM; Erickson LA; McIver B; Grebe SK
J Clin Endocrinol Metab; 2009 Dec; 94(12):5001-9. PubMed ID: 19850689
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.
Jin L; Sebo TJ; Nakamura N; Qian X; Oliveira A; Majerus JA; Johnson MR; Lloyd RV
Diagn Mol Pathol; 2006 Sep; 15(3):136-43. PubMed ID: 16932068
[TBL] [Abstract][Full Text] [Related]
13. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
14. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
15. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
Jakubowski M; Hunt JL
Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
[TBL] [Abstract][Full Text] [Related]
17. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
Lee JH; Lee ES; Kim YS; Won NH; Chae YS
Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutations in an Italian cohort of thyroid cancers.
Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]